Information Provided By:
Fly News Breaks for December 20, 2016
ACAD
Dec 20, 2016 | 08:17 EDT
Leerink analyst Paul Matteis notes that ACADIA has announced positive top-line data from its Phase 2 study of pimavanserin in Alzheimer's Disease Psychosis. While the analyst believes the benefit looks "modest," he says the announcement represents "clear upside to expectations," which were low into the event. Leerink has a Market Perform on the shares.
News For ACAD From the Last 2 Days
There are no results for your query ACAD